ALL
Clinical trials for ALL explained in plain language.
Never miss a new study
Get alerted when new ALL trials appear
Sign up with your email to follow new studies for ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New stem cell processing method aims to prevent transplant complications
Disease control Recruiting nowThis study tests a new automated method to select specific stem cells (CD34+) for transplant in people with blood cancers like leukemia or lymphoma. The goal is to lower the risk of graft-versus-host disease, a serious complication where donor cells attack the patient's body. Abo…
Matched conditions: ALL
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated May 26, 2026 08:08 UTC
-
Cord blood transplants offer hope for kids without a donor match
Disease control Recruiting nowThis study tests whether a cord blood transplant can help children and young adults (up to age 21) with life-threatening blood cancers or genetic blood disorders who do not have a matched family donor. The main goal is to see how many patients survive one year after the transplan…
Matched conditions: ALL
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:07 UTC
-
New hope for leukemia patients: drug targets hidden cancer cells after transplant
Disease control Recruiting nowThis study tests a drug called Inotuzumab Ozogamicin (INO) in people with acute lymphoblastic leukemia (ALL) who still have tiny amounts of leukemia cells (called minimal residual disease, or MRD) after a stem cell transplant. The goal is to see if INO can clear these leftover ce…
Matched conditions: ALL
Phase: PHASE2 • Sponsor: Sheng-Li Xue, MD • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Engineered immune cells target tough leukemia in new trial
Disease control Recruiting nowThis study tests a treatment called CD19 CAR-T cell therapy in 50 adults with a specific type of leukemia (Ph+ ALL). The therapy uses a patient's own immune cells that are modified to find and kill leukemia cells. The main goal is to see if the treatment can make the cancer disap…
Matched conditions: ALL
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New hope for young leukemia patients: targeted drug added to chemo shows promise
Disease control Recruiting nowThis early-phase study is testing whether adding the targeted drug ruxolitinib to standard chemotherapy is safe for adolescents and young adults (ages 12-39) with a specific high-risk type of acute lymphoblastic leukemia (Ph-like ALL). The trial aims to find the best dose and che…
Matched conditions: ALL
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 19, 2026 11:46 UTC
-
Crushed pill study aims to help kids with blood cancer who Can't swallow tablets
Knowledge-focused Recruiting nowThis study looks at how the body processes venetoclax when the tablets are crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured.…
Matched conditions: ALL
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated May 26, 2026 08:11 UTC
-
Amish and mennonite communities invited to join medical research registry
Knowledge-focused Recruiting nowThis study creates a contact registry for Amish and Mennonite people who want to take part in future medical research. Researchers will use the registry to find volunteers whose family health history matches new studies. The goal is to learn more about health conditions that affe…
Matched conditions: ALL
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated May 26, 2026 08:10 UTC
-
15-Year safety check for new blood cancer cell therapy
Knowledge-focused Recruiting nowThis study follows about 1,000 people who previously received an experimental T-cell therapy (TSC-100 or TSC-101) for blood cancers like AML, ALL, or MDS. Researchers will monitor participants for up to 15 years to track any side effects and see how well the therapy works over ti…
Matched conditions: ALL
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC